Wockhardt Ltd
Wockhardt Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹721Cr
- +2.9% YoY
- Net profit
- ₹20Cr
- Q3 FY24: −₹86 Cr
- Margin
- 18%
- +13 pp YoY
Guidance rank: #17 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Wockhardt Ltd Q3 FY25 key numbers
- Revenue
- EBITDA for 9MFY25 stood at Rs. 339 crore, up 89% compared to Rs. 180 crore for 9MFY24.
As stated in Wockhardt Ltd's Q3 FY25 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Wockhardt Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3 FY25 Revenue: Rs. 725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. 709 crore). Q3 FY25 EBITDA: Rs. 100 crore vs Rs. 67 crore in Q3 FY24 (YoY growth of ~49%).
From Wockhardt Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY25 Revenue: Rs. 725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. 709 crore).
- 9MFY25 Revenue: Rs. 2,290 crore versus Rs. 2,129 crore in 9MFY24, an 8% year-on-year growth.
- EBITDA in Q3 FY25 improved 50% year-on-year to Rs. 100 crore from Rs. 67 crore in Q3 FY24.
- EBITDA for 9MFY25 stood at Rs. 339 crore, up 89% compared to Rs. 180 crore for 9MFY24.
- India Branded Business Q3 FY25 revenue: Rs. 114 crore; 9MFY25 revenue: Rs. 361 crore.
- Irish Business Q3 FY25 revenue: Rs. 46 crore; 9MFY25 revenue: Rs. 134 crore.
2 more points from Wockhardt Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Wockhardt Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Wockhardt Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Wockhardt Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Wockhardt Ltd said on order book & pipeline — free account, 30 seconds.
Wockhardt Ltd — Quarterly revenue & net profit
Wockhardt Ltd Q3 FY25 results — key figures
| ₹ Cr | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 721 | 701 | +2.9% | 809 | -10.9% |
| Operating profit (EBITDA) | 128 | 37 | +245.9% | 110 | +16.4% |
| Operating margin | 18% | 5% | +13 pp | 14% | +4 pp |
| Profit before tax | 21 | -87 | — | -9 | — |
| Net profit (PAT) | 20 | -86 | — | -16 | — |
| EPS (₹) | 0.86 | -5.76 | — | -1.43 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹969 Cr, net profit ₹73 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Wockhardt's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q3 FY24 earnings call analysis →
- Q3 FY23 earnings call →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharmaceuticals (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- NGL Fine Chem (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
- Themis Medicare (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY25 earnings call — and how it ranks against…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Wockhardt Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Wockhardt Ltd Q3 FY25 results?
Q3 FY25 Revenue: Rs. 725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. 709 crore). Q3 FY25 EBITDA: Rs. 100 crore vs Rs. 67 crore in Q3 FY24 (YoY growth of ~49%).
What is Wockhardt Ltd share price analysis?
Wockhardt Ltd currently shows a neutral. The stock trades at a P/E of 85.0 with a market cap of ₹33,897 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Wockhardt Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.